Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor

Inclusion: - Subject must remain on current antiretroviral therapy during screening until a new regimen is initiated. - Subject demonstrates reduced susceptibility to lopinavir. - Subject's two most recent viral loads obtained after at least 16 weeks of lopinavir/ritonavir therapy, and while still on Kaletra therapy must be at least 1,000 copies/mL. - The Kaletra regimen must be the subject's second PI containing regimen and must not contain any other PIs. - Subject is at least 18 years of age. - Subject has not been treated for an active opportunistic infection within 30 days of screening. Exclusion: - Subject has a history of active substance abuse or psychiatric illness that could preclude compliance to the protocol. - Female subject pregnant or lactating. - Use of an Investigational drug within 30 days prior to the initiation of drug dosing. - Subject is receiving systemic chemotherapy. - Subject has a history of acute or chronic pancreatitis.